纤溶酶原激活物抑制剂-1与肾损伤的相关性分析

目的:探讨纤溶酶原激活物抑制剂-1(PAI-1)与肾损伤的相关性。方法:将慢性肾功能衰竭(CRF)120例患者设为观察组;同期选择健康体检者120例设为对照组。对2组PAI-1进行比较分析。结果:观察组的PAI-1含量明显高于对照组[(12.66±3.24)Au/m L vs(6.97±2.33)Au/m L(P0.05)]。随着病程的延长,观察组的PAI-1含量也呈现明显增加的趋势(P0.05)。观察组的TC、TG与LDL值明显高于对照组(P0.05)。Spearman相关性分析表明观察组的PAI-1含量与血脂各项指标均无显著相关,但是与病程有明显相关性(P0.05)。结论:PAI-1在肾损伤时明显表达增强,与疾病的病程有明显相关性,与血脂表达不存在明显相关性。

The correlation analysis of plasminogen activator inhibitor-1 and renal impairment

Objective: To investigate the correlation of plasminogen activator inhibitor-1 and renal impairment. Methods: From August 2011 to February 2014 in our hospital, selected 120 patients with chronic renal failure as the observation group, choose 120 healthy normal cases as the control group at the same period in our hospital, two groups were given the plasminogen activator inhibitor -1 (PAI-1) and lipid conventional indicators detection and were given the correlation analysis based on clinical data. Results: The PAI-1 contents in the observation group were 12.66 ± 3.24 AU / ml, the control group were 6.97 ± 2.33 AU / ml, the PAI-1 contents in the treatment group were significantly higher (P <0.05). With increased duration, the PAI-1 contents in the observation group were also showed significant increased trend (P <0.05). The TC, TG and LDL values in the observation group were significantly higher that compared to significant differences (P <0.05).Spearman correlation analysis showed that PAI-1 contents ere not significantly related to the lipid in the observation group, but had significant correlation with the duration (P <0.05). Conclusion: PAI-1 expression in renal injury was significantly enhanced, there is significant correlation with disease progression, but there is no significant correlation to expression lipid.